Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,736.40
(
1.03%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
111.03
(
0.61%
)
Bitcoin
77,230.00
(
1.18%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122916
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 237898

Monday, 12/18/2023 7:38:21 PM

Monday, December 18, 2023 7:38:21 PM

Post# of 257473
CARA—(-49%)—flops again in pruritis/AD—discontinues program:

https://finance.yahoo.com/news/cara-therapeutics-announces-outcome-dose-120000127.html

Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today